133 Publications (Page 3 of 6)
2012
Single-Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia (AML): Validation in Two Independent Sample Sets From ECOG and SWOG Trials
Cesano, AlessandraWillman, Cheryl LKopecky, Kenneth JGayko, UrtePutta, SantoshLouie, BrentWestfall, MattPurvis, NormanSpellmeyer, DavidMarimpietri, CarolHackett, JamesShi, JingPaietta, ElisabethTallman, Martin SCripe, Larry DAtwater, Susan KAppelbaum, Frederick R and Radich, Jerald P
Blood, vol. 120, (no. 21), pp. 2489, 2012-11-16. | Journal Article
2011
A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia.
Lancet, JeffreyRavandi, FRicklis, R MCripe, L DKantarjian, H MGiles, Francis JList, Alan FChen, TAllen, R SFox, J AMichelson, G C and Karp, J E
Leukemia, vol. 25, (no. 12), pp. 1808-14, 2011/Dec. | Journal Article
 
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.
Levis, Mark JLevis, MarkRavandi, FarhadRavandi Kashani, FarhadWang, Eunice SWang, Eunice SBaer, Maria RBaer, Maria RPerl, AlexanderPerl, AlexanderCoutré, Steven ECoutre, StevenErba, HarryErba, HarryStuart, Robert KStuart, Robert KBaccarani, MicheleBaccarani, MicheleCripe, Larry DCripe, Larry DTallman, Martin STallman, Martin SMeloni, GiovannaMeloni, GiovannaGodley, Lucy AGodley, Lucy ALangston, Amelia ALangston, Amelia AAmadori, SergioAmadori, SergioLewis, Ian DLewis, Ian DNagler, ArnonNagler, ArnonStone, RichardStone, RichardYee, KarenYee, KarenAdvani, AnjaliAdvani, AnjaliDouer, DanDouer, DanWiktor-Jedrzejczak, WWiktor-Jedrzejczak, WJuliusson, GunnarJuliusson, GunnarLitzow, Mark RLitzow, Mark RPetersdorf, StephenPetersdorf, StephenSanz, MiguelSanz, MiguelKantarjian, Hagop MKantarjian, HagopSato, TakashiSato, TakashiTremmel, LotharTremmel, LotharBensen-Kennedy, Debra MBensen-Kennedy, Debra MSmall, DonaldSmall, DonaldSmith, B D and Smith, B Douglas
Blood, vol. 117, (no. 12), pp. 3294-301, 2011/Mar/24. | Journal Article
 
Single Cell Network Profiling (SCNP) Functionally Characterizes FLT3 Pathway Deregulation in Non-M3 Acute Myeloid Leukemia (AML) and Provides Prognostic Value Independent From Mutational Status
Cesano, AlessandraPutta, SantoshMathi, KavitaRosen, David BGayko, UrteHawtin, Rachael ECripe, Larry DSun, ZhuoxinTallman, Martin S and Paietta, Elisabeth
Blood, vol. 118, (no. 21), pp. 2512, 2011-11-18. | Journal Article
 
The Impact of Obesity on the Presentation & Outcome of Adult Acute Myeloid Leukemia (AML) - ECOG Studies E1900 & E3999
Foran, James MSun, ZhuoxinFernandez, Hugo FCripe, Larry DKetterling, Rhett PRacevskis, JanisLuger, Selina MPaietta, ElisabethLazarus, Hillard MLitzow, Mark R and Tallman, Martin S
Blood, vol. 118, (no. 21), pp. 2568, 2011-11-18. | Journal Article
 
Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group.
Sayar, HamidChan, RebeccaOrschell, Christie MChan, Edward MYu, ZhangshengHood, DanielPlett, ArturYang, ZhenyunHui, Chua LNabinger, Sarah CKohlbacher, Kristopher JWest, Evan SWalter, AmandaSampson, CarolWu, Jingwei and Cripe, Larry D
Leukemia research, vol. 35, (no. 8), pp. 1108-10, 2011/Aug. | Journal Article
 
Trustworthiness.
Cripe, Larry D
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 29, (no. 25), pp. 3483-6, 2011/Sep/1. | Journal Article
 
Trustworthiness.
Cripe, Larry D
(pp. 3483-3486). September 1, 2011
2010
A Pathway-focused GSEA Platform In AML That Interrogates Interaction of Flt3ITD and tMLL with Their Epigenetic Targets (p16INK4a, DAPK1, and RUNX3), While Accurately Reporting Broad-based AML Prognosis and Targeting-agent Sensitivity
Baghdadi, Tareq AlGoswami, ChirayuSayar, HamidSargent, Katie JCripe, LarryLi, LangShanmugam, Rajasubramaniam and Boswell, H. Scott
Blood, vol. 116, (no. 21), pp. 1660, 2010-11-19. | Journal Article
 
Characterization of FLT3 Pathway Deregulation by Single Cell Network Profiling (SCNP) Stratifies AML Patients Beyond Molecular Profiling
Rosen, David BPutta, SantoshGayko, UrteCesano, AlessandraCripe, LarrySun, ZhuoxinLitzow, Mark RUno, HajimeTallman, Martin S and Paietta, Elisabeth
Blood, vol. 116, (no. 21), pp. 2739, 2010-11-19. | Journal Article
 
Cyclic Administration of Combination of Sorafenib and Vorinostat In Poor-Risk AML: A Pharmacodynamically-Oriented Extended Phase I Trial
Sayar, HamidCripe, LarryCangany, MaryWeisenbach, JillSargent, Katie JGoswami, ChirayuLi, LangWilson-Weekes, AnniqueShanmugam, Rajasubramaniam and Boswell, H. Scott
Blood, vol. 116, (no. 21), pp. 3272, 2010-11-19. | Journal Article
 
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group.
Litzow, Mark ROthus, MeganCripe, Larry DGore, Steven DLazarus, Hillard MLee, Sandra JBennett, John MPaietta, Elisabeth MDewald, Gordon WRowe, Jacob M and Tallman, Martin S
British journal of haematology, vol. 148, (no. 2), pp. 217-25, 2010/Jan. | Journal Article
 
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Friedberg, Jonathan WSharman, JeffSweetenham, JohnJohnston, Patrick LVose, Julie MLa Casce, Ann SLacasce, AnnSchaefer-Cutillo, JuliaDe Vos, SvenSinha, RajniLeonard, John PCripe, Larry DGregory, Stephanie ASterba, Michael PLowe, Ann MLevy, Ronald and Shipp, Margaret A
Blood, vol. 115, (no. 13), pp. 2578-85, 2010/Apr/1. | Journal Article
 
Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.
Mesa, Ruben AYao, XiaopanCripe, Larry DLi, Chin YLitzow, MarkPaietta, Elisabeth MRowe, Jacob MTefferi, Ayalew and Tallman, Martin S
Blood, vol. 116, (no. 22), pp. 4436-8, 2010/Nov/25. | Journal Article
 
Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia.
Nelson, Robert PYu, MenggangSchwartz, JenniferRobertson, Michael JHromas, Robert AFausel, C AVance, Gail HDlouhy, Stephen RBaute, J ACox, E AWood, L LSrivastava, ShivaniRobertson, KentHaut, P RFarag, Sherif SAbonour, RafatCornetta, Kenneth G and Cripe, Larry D
Bone marrow transplantation, vol. 45, (no. 8), pp. 1300-8, 2010/Aug. | Journal Article
 
Monosomal Karyotype (MK) In Older Patients with Acute Myeloid Leukemia (AML) on Eastern Cooperative Oncology Group (ECOG) Therapeutic Trials: Poor Prognostic Impact of MK, but Not of Monosomy 7
Strickland, Stephen AStrickland, Stephen ASun, ZhuoxinSun, ZhuoxinKetterling, Rhett PKetterling, Rhett PCherry, Athena MCherry, Athena MCripe, Larry DCripe, Larry DDewald, GordonDewald, GordonHiggins, Rodney RHiggins, Rodney RLazarus, Hillard MLazarus, Hillard MLitzow, Mark RLitzow, Mark RLuger, Selina MLuger, Selina MPaietta, ElisabethPaietta, ElisabethRowe, Jacob MRowe, Jacob MUno, HajimeUno, HajimeVance, Gail HVance, Gail HTallman, Martin S and Tallman, Martin S
Blood, vol. 116, (no. 21), pp. 579, 2010-11-19. | Journal Article
 
Single-Cell Network Profiliing (SCNP) Signatures Independently Predict Response to Induction Therapy In Older Patients with Acute Myeloid Leukemia (AML)
Cesano, AlessandraPutta, SantoshGayko, UrteHackett, JamesRosen, David BCripe, LarrySun, ZhuoxinUno, HajimeLitzow, Mark RTallman, Martin S and Paietta, Elisabeth
Blood, vol. 116, (no. 21), pp. 2695, 2010-11-19. | Journal Article
 
Specimen Source (BM or PB) Does Not Affect Proteomic Signaling In Patients with AML and Circulating Blasts
Cesano, AlessandraRosen, David BPutta, SantoshGayko, UrteCripe, LarrySun, ZhuoxinUno, HajimeLitzow, Mark RTallman, Martin S and Paietta, Elisabeth
Blood, vol. 116, (no. 21), pp. 2693, 2010-11-19. | Journal Article
 
Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999.
Cripe, Larry DCripe, Larry DUno, HajimeUno, HajimePaietta, Elisabeth MPaietta, Elisabeth MLitzow, Mark RLitzow, Mark RKetterling, Rhett PKetterling, Rhett PBennett, John MBennett, John MRowe, Jacob MRowe, Jacob MLazarus, Hillard MLazarus, Hillard MLuger, Selina MLuger, SelinaTallman, Martin S and Tallman, Martin S
Blood, vol. 116, (no. 20), pp. 4077-85, 2010/Nov/18. | Journal Article
2009
A Phase 2 Dose Regimen Optimization Study of Three Schedules of Voreloxin as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
Ravandi, FarhadKantarjian, Hagop MCripe, Larry DMaris, MichaelCooper, MaureenDakhil, Shaker RStone, Richard MTurturro, FrancescoChen, TianlingMahadocon, KristiFox, JudithBerman, CraigMichelson, Glenn C and Stuart, Robert K
Blood, vol. 114, (no. 22), pp. 1037, 2009-11-20. | Journal Article
 
A piece of my mind. Giving up.
Cripe, Larry D
JAMA : the journal of the American Medical Association, vol. 301, (no. 17), pp. 1747-8, 2009/May/6. | Journal Article
 
Dying pretty.
Cripe, Larry D
Journal of palliative medicine, vol. 12, (no. 9), pp. 839-40, 2009/Sep. | Journal Article
 
Foreword. The discovered story: the evolution of truth in cancer narratives
Cripe, Larry D
Literature and medicine, vol. 28, (no. 2), pp. vi, 2009-Fall. | Journal Article
 
Giving Up
Cripe, Larry D
JAMA, vol. 301, (no. 17), May 6, 2009. | Journal Article
 
Phase 1b/2 Pharmacokinetic/Pharmacodynamic (PK/PD) Study of Combination Voreloxin and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Patients
Lancet, Jeffrey ERoboz, Gail JCripe, Larry DMaris, MichaelList, Alan FFox, JudithMichelson, Glenn C and Karp, Judith
Blood, vol. 114, (no. 22), pp. 635, 2009-11-20. | Journal Article